APA
Bonvalot S., Rutkowski P. L., Thariat J., Carrère S., Ducassou A., Sunyach M., Agoston P., Hong A., Mervoyer A., Rastrelli M., Moreno V., Li R. K., Tiangco B., Herraez A. C., Gronchi A., Mangel L., Sy-Ortin T., Hohenberger P., de Baère T., Le Cesne A., Helfre S., Saada-Bouzid E., Borkowska A., Anghel R., Co A., Gebhart M., Kantor G., Montero A., Loong H. H., Vergés R., Lapeire L., Dema S., Kacso G., Austen L., Moureau-Zabotto L., Servois V., Wardelmann E., Terrier P., Lazar A. J., Bovée J. V. M. G., Le Péchoux C. & Papai Z. (20200619). NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. : The Lancet. Oncology.
Chicago
Bonvalot Sylvie, Rutkowski Piotr L, Thariat Juliette, Carrère Sébastien, Ducassou Anne, Sunyach Marie-Pierre, Agoston Peter, Hong Angela, Mervoyer Augustin, Rastrelli Marco, Moreno Victor, Li Rubi K, Tiangco Béatrice, Herraez Antonio Casado, Gronchi Alessandro, Mangel László, Sy-Ortin Teresa, Hohenberger Peter, de Baère Thierry, Le Cesne Axel, Helfre Sylvie, Saada-Bouzid Esma, Borkowska Aneta, Anghel Rodica, Co Ann, Gebhart Michael, Kantor Guy, Montero Angel, Loong Herbert H, Vergés Ramona, Lapeire Lore, Dema Sorin, Kacso Gabriel, Austen Lyn, Moureau-Zabotto Laurence, Servois Vincent, Wardelmann Eva, Terrier Philippe, Lazar Alexander J, Bovée Judith V M G, Le Péchoux Cécile and Papai Zsusanna. 20200619. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. : The Lancet. Oncology.
Harvard
Bonvalot S., Rutkowski P. L., Thariat J., Carrère S., Ducassou A., Sunyach M., Agoston P., Hong A., Mervoyer A., Rastrelli M., Moreno V., Li R. K., Tiangco B., Herraez A. C., Gronchi A., Mangel L., Sy-Ortin T., Hohenberger P., de Baère T., Le Cesne A., Helfre S., Saada-Bouzid E., Borkowska A., Anghel R., Co A., Gebhart M., Kantor G., Montero A., Loong H. H., Vergés R., Lapeire L., Dema S., Kacso G., Austen L., Moureau-Zabotto L., Servois V., Wardelmann E., Terrier P., Lazar A. J., Bovée J. V. M. G., Le Péchoux C. and Papai Z. (20200619). NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. : The Lancet. Oncology.
MLA
Bonvalot Sylvie, Rutkowski Piotr L, Thariat Juliette, Carrère Sébastien, Ducassou Anne, Sunyach Marie-Pierre, Agoston Peter, Hong Angela, Mervoyer Augustin, Rastrelli Marco, Moreno Victor, Li Rubi K, Tiangco Béatrice, Herraez Antonio Casado, Gronchi Alessandro, Mangel László, Sy-Ortin Teresa, Hohenberger Peter, de Baère Thierry, Le Cesne Axel, Helfre Sylvie, Saada-Bouzid Esma, Borkowska Aneta, Anghel Rodica, Co Ann, Gebhart Michael, Kantor Guy, Montero Angel, Loong Herbert H, Vergés Ramona, Lapeire Lore, Dema Sorin, Kacso Gabriel, Austen Lyn, Moureau-Zabotto Laurence, Servois Vincent, Wardelmann Eva, Terrier Philippe, Lazar Alexander J, Bovée Judith V M G, Le Péchoux Cécile and Papai Zsusanna. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. : The Lancet. Oncology. 20200619.